Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 16:05 ET | Source: IRIDEX Corporation

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and...
May 05, 2026 15:15 ET | Source: Neuvasq Biotechnologies

Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026

Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) -- Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing,...
May 05, 2026 14:18 ET | Source: Spherix Global Insights

Lupus Patients Continue to Navigate Delayed Diagnosis, High Disease Burden, and Complex Treatment Journeys, According to Spherix Global Insights

Exton, PA, May 05, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Voice Dynamix™: Systemic Lupus Erythematosus (SLE) 2026 highlight a market still defined by high...
May 05, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight

New York, USA, May 05, 2026 (GLOBE NEWSWIRE) -- Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations |...
May 05, 2026 08:12 ET | Source: Ocugen

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...
May 05, 2026 04:00 ET | Source: Oculis Holding AG

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...
May 05, 2026 04:00 ET | Source: Oculis Holding AG

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular...
May 04, 2026 16:30 ET | Source: BioAge Labs, Inc.

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular...
May 04, 2026 16:01 ET | Source: Ocugen

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
May 04, 2026 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn., May ...